Therapy of chronic graft-versus-host disease - PubMed (original) (raw)

Review

Therapy of chronic graft-versus-host disease

Mukta Arora. Best Pract Res Clin Haematol. 2008 Jun.

Abstract

Chronic graft-versus-host disease (cGVHD) is a common complication after hematopoietic-cell transplant and remains the leading cause of late non-relapse mortality. Standard treatment includes a combination of a calcineurin inhibitor and corticosteroids. Prolonged steroid use is required, with more than 50% of patients continuing immunosuppression beyond 2 years. There is no standard second-line therapy for cGVHD. Many agents have been reported in small case series, but the studies are heterogeneous in patient selection and response criteria. There is a need for a systematic study of agents for secondary therapy of cGVHD. In addition, both cGVHD and its treatment are associated with severe complications, including life-threatening infections, reduced quality of life, and psychosocial disturbances. A multidisciplinary approach to evaluating and managing patients with cGVHD is preferred, and disciplined, prospective study of new therapies is essential to make further progress in its understanding and treatment.

PubMed Disclaimer

Cited by

Topical treatment of oral chronic graft-versus-host- disease in hematopoietic stem cell transplant recipients: A systematic review.
Haas L, Cruz-Pamplona M. Haas L, et al. J Clin Exp Dent. 2023 May 1;15(5):e420-e427. doi: 10.4317/jced.60138. eCollection 2023 May. J Clin Exp Dent. 2023. PMID: 37214749 Free PMC article. Review.
Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease.
Mansourian A, Bahar B, Moosavi MS, Amanlou M, Babaeifard S. Mansourian A, et al. J Dent (Tehran). 2017 Nov;14(6):313-320. J Dent (Tehran). 2017. PMID: 29942325 Free PMC article.
Previously Activated Psoralen: A Possible Novel Format of Psoralen Used in the Treatment of Graft-versus-host Disease.
Hu X, Qian L, Chen X, Shen J. Hu X, et al. West Indian Med J. 2015 Mar;64(2):135-7. doi: 10.7727/wimj.2014.166. Epub 2015 Jan 27. West Indian Med J. 2015. PMID: 26360687 Free PMC article.
Graft-versus-host disease affecting oral cavity. A review.
Margaix-Muñoz M, Bagán JV, Jiménez Y, Sarrión MG, Poveda-Roda R. Margaix-Muñoz M, et al. J Clin Exp Dent. 2015 Feb 1;7(1):e138-45. doi: 10.4317/jced.51975. eCollection 2015 Feb. J Clin Exp Dent. 2015. PMID: 25810826 Free PMC article. Review.
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.
Mielke S, Lutz M, Schmidhuber J, Kapp M, Ditz D, Ammer J, Einsele H, Grigoleit GU, Holler E, Wolff D. Mielke S, et al. Bone Marrow Transplant. 2014 Nov;49(11):1412-8. doi: 10.1038/bmt.2014.170. Epub 2014 Aug 4. Bone Marrow Transplant. 2014. PMID: 25089598

References

1. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276. - PubMed
1. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72:555–561. - PubMed
1. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–51. - PubMed
1. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9:38–45. - PubMed
1. Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB) Biol Blood Marrow Transplant. 2007;13:1145–1152. - PubMed

Therapy of chronic graft-versus-host disease - PubMed (original) (raw)